home / stock / bysi / bysi news

BYSI News and Press, BeyondSpring Inc. From 10/25/19

Stock Information
Company Name: BeyondSpring Inc.
Stock Symbol: BYSI
Market: NASDAQ
Website: beyondspringpharma.com
Menu
BYSI BYSI Quote BYSI Short BYSI News BYSI Articles BYSI Message Board
Get BYSI Alerts

News, Short Squeeze, Breakout and More Instantly...
BYSI - BeyondSpring Announces Pricing of Ordinary Shares

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, toda...
BYSI - BeyondSpring down 19% on proposed public offering

BeyondSpring (NASDAQ: BYSI ) tanks  19.2%  in pre-market after the company announced a public offering led by Decheng Capital. More news on: BeyondSpring Inc., Healthcare stocks news, Read more ...

BYSI - BeyondSpring commences late-stage study of Plinabulin for preventing chemo-induced neutropenia

The first patient has been enrolled  in a Phase 3 clinical trial, Study 106, evaluating BeyondSpring's ( BYSI -4.1% ) lead candidate Plinabulin for the prevention of chemotherapy-induced neutropenia (CIN) (abnormally low levels of a type of immune cell call neutrophils). ...

BYSI - BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia

NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has enrolled its first patient in a Phase 3, Study 106, clinical t...
BYSI - BeyondSpring's Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors

NEW YORK, Oct. 17, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the United States Patent Office has granted the Company a new patent, U.S. Patent No. 10,357,4...

BYSI - Cell Journals Publishes BeyondSpring's New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation

NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that Cell Press publications Chem and Cell Reports , two peer-reviewed s...

BYSI - BeyondSpring Presents Novel Trial Design for DUBLIN-3 Study BPI-2358-103 at ESMO Congress 2019

NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immune-oncology cancer therapies, today announced that the Company’s novel trial design for DUBLIN-3 (Study BPI-2358-103) for ...
BYSI - BeyondSpring's Plinabulin Continues to Build on Superior Product Profile in Breast Cancer Trial for Neutropenia Prevention

NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that a Company abstract with findings from BeyondSpring’s Study 106 has been accepted for p...

BYSI - BeyondSpring Inc. (BYSI) Q2 2019 Earnings Call Transcript

Image source: The Motley Fool. BeyondSpring Inc.   (NASDAQ: BYSI) Q2 2019 Earnings Call Sep 18, 2019 , 8:00 a.m. ET Operator Continue reading

BYSI - BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2019 Results - Earnings Call Transcript

BeyondSpring Inc. (BYSI) Q2 2019 Earnings Conference Call September 18, 2019 08:00 ET Company Participants Stephen Kilmer - IR Lan Huang - Chairman & CEO Ramon Mohanlal - EVP of Research and Development and Chief Medical Officer Richard Daly - COO Edward Liu - CFO Conf...
Previous 10 Next 10